Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Trisha M. Tee"'
IKZF1 gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia
Autor:
Britt M. T. Vervoort, Miriam Butler, Kari J.T. Grünewald, Dorette S. van Ingen Schenau, Trisha M. Tee, Luc Lucas, Alwin D. R. Huitema, Judith M. Boer, Beat C. Bornhauser, Jean-Pierre Bourquin, Peter M. Hoogerbrugge, Vincent H.J. van der Velden, Roland P. Kuiper, Laurens T. van der Meer, Frank N. van Leeuwen
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
IKZF1-deletions occur in 10-15% of patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and predict a poor outcome. However, the impact of IKZF1-loss on sensitivity to drugs used in contemporary treatment protocols has remained under
Externí odkaz:
https://doaj.org/article/70f5749bff5943bb9814e9df3159f0f2
Autor:
Beat Bornhauser, Roland P. Kuiper, Steven M. Kornblau, Britt M.T. Vervoort, Jiangyan Yu, Rico Hagelaar, Fieke W Hoff, Frank N. van Leeuwen, Dorette van Ingen Schenau, Maria Pamela Dobay, Trisha M Tee, Laurens T. van der Meer, Silvia Jenni, Jules P.P. Meijerink, Jean-Pierre Bourquin, Miriam Butler
Publikováno v:
Blood, 138(23), 2383-2395. AMER SOC HEMATOLOGY
Blood, 138, 23, pp. 2383-2395
Blood, 138, 2383-2395
Blood, 138, 23, pp. 2383-2395
Blood, 138, 2383-2395
Contains fulltext : 241347.pdf (Publisher’s version ) (Closed access) Asparaginase (ASNase) therapy has been a mainstay of acute lymphoblastic leukemia (ALL) protocols for decades and shows promise in the treatment of a variety of other cancers. To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db47fa4b7f953cb27d3df3b78bffe81d
https://doi.org/10.1182/blood.2021011787
https://doi.org/10.1182/blood.2021011787
Autor:
Frank N. van Leeuwen, Ahmed Dahaoui, Dorette van Ingen Schenau, Laurens T. van der Meer, Rico Hagelaar, Titine Ruiter, Trisha M Tee
Publikováno v:
Blood. 138:2269-2269
Background: MLL (KMT2A)-rearranged acute lymphoblastic leukemia (MLLr ALL) is a rare but aggressive subset that represents 5% of childhood ALL cases, and accounts for about 70% of infant leukemias. While overall survival in these young children is ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b40970b0042c0bf9c1242f38e53725d
https://doi.org/10.1182/blood-2021-145308
https://doi.org/10.1182/blood-2021-145308